Bio Green Med Solution, Inc.

Regulatory Filings • Jul 17, 2017

CORRESP 1 filename1.htm

CYCLACEL PHARMACEUTICALS, INC.

200 Connell Drive, Suite 1500

Berkeley Heights, NJ 07922

July 17, 2017

Via EDGAR

Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

Attention:
Johnny Gharib

Re: Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed on May 26, 2017, as amended on June 30, 2017, July 6, 2017 and July 17, 2017 File No. 333-218305

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 be accelerated to Monday, July 17, 2017, at 5:15 p.m., EST, or as soon as thereafter practicable.

Any questions should be addressed to Joel I. Papernik, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York, telephone (212) 692-6774.

Thank you for your attention to this matter.

Very truly yours, Cyclacel Pharmaceuticals, Inc. /s/ Spiro Rombotis Spiro Rombotis Chief Executive Officer

cc:
Suzanne Hayes Johnny Gharib Erin Jaskot
Cyclacel Pharmaceuticals, Inc.
Paul McBarron

Field: Page; Sequence: 1; Options: Last

Field: /Page